KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Total Liabilities (2017 - 2025)

Bionano Genomics' Total Liabilities history spans 7 years, with the latest figure at $29.3 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 23.99% year-over-year to $29.3 million; the TTM value through Sep 2025 reached $29.3 million, down 23.99%, while the annual FY2024 figure was $41.3 million, 65.08% down from the prior year.
  • Total Liabilities for Q3 2025 was $29.3 million at Bionano Genomics, down from $30.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $118.2 million in Q4 2023 and bottomed at $10.9 million in Q2 2021.
  • The 5-year median for Total Liabilities is $40.0 million (2021), against an average of $45.1 million.
  • The largest annual shift saw Total Liabilities surged 236.45% in 2022 before it crashed 65.08% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $40.0 million in 2021, then surged by 45.33% to $58.1 million in 2022, then skyrocketed by 103.51% to $118.2 million in 2023, then plummeted by 65.08% to $41.3 million in 2024, then dropped by 29.14% to $29.3 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Total Liabilities are $29.3 million (Q3 2025), $30.6 million (Q2 2025), and $30.2 million (Q1 2025).